Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Rabia E, Garambois V, Dhommée C, Larbouret C, Lajoie L, Buscail Y, Jimenez-Dominguez G, Choblet-Thery S, Liaudet-Coopman E, Cerutti M, Jarlier M, Ravel P, Gros L, Pirot N, Thibault G, Zhukovsky EA, Gérard PE, Pèlegrin A, Colinge J, Chardès T. Rabia E, et al. Among authors: gros l. Front Immunol. 2023 Apr 20;14:1168444. doi: 10.3389/fimmu.2023.1168444. eCollection 2023. Front Immunol. 2023. PMID: 37153618 Free PMC article.
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P, Lajoie L, Mallavialle A, Alcaraz LB, Mansouri H, Fenou L, Garambois V, Rubio L, David T, Coenon L, Boissière-Michot F, Chateau MC, Ngo G, Jarlier M, Villalba M, Martineau P, Laurent-Matha V, Roger P, Guiu S, Chardès T, Gros L, Liaudet-Coopman E. Desroys du Roure P, et al. Among authors: gros l. J Immunother Cancer. 2024 Jan 30;12(1):e007135. doi: 10.1136/jitc-2023-007135. J Immunother Cancer. 2024. PMID: 38290768 Free PMC article.
STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma.
Fauvre A, Machu M, Merienne A, Vie N, Bessede T, Robin M, Garambois V, Taffoni C, Laguette N, Gervois-Segain N, Jarry A, Labarriere N, Allory Y, Larbouret C, Gros L, Tosi D, Solit DB, Pourquier P, Houédé N, Gongora C. Fauvre A, et al. Among authors: gros l. Clin Transl Med. 2024 Sep;14(9):e70011. doi: 10.1002/ctm2.70011. Clin Transl Med. 2024. PMID: 39269751 Free PMC article. No abstract available.
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment.
Bruciamacchie M, Garambois V, Vie N, Bessede T, Michaud HA, Chepeaux LA, Gros L, Bonnefoy N, Robin M, Brager D, Bigot K, Evrard A, Pourquier P, Colinge J, Mathonnet M, Belhabib I, Jean C, Bousquet C, Colombo PE, Jarlier M, Tosi D, Gongora C, Larbouret C. Bruciamacchie M, et al. Among authors: gros l. Br J Cancer. 2024 Nov 29. doi: 10.1038/s41416-024-02904-3. Online ahead of print. Br J Cancer. 2024. PMID: 39613844
L’humanisation des soins en réanimation.
Gros L. Gros L. Rev Infirm. 2024 Dec;73(306):53-54. doi: 10.1016/j.revinf.2024.11.020. Epub 2024 Dec 2. Rev Infirm. 2024. PMID: 39667844 French. No abstract available.
Lung cancer research and treatment: global perspectives and strategic calls to action.
Meyer ML, Peters S, Mok TS, Lam S, Yang PC, Aggarwal C, Brahmer J, Dziadziuszko R, Felip E, Ferris A, Forde PM, Gray J, Gros L, Halmos B, Herbst R, Jänne PA, Johnson BE, Kelly K, Leighl NB, Liu S, Lowy I, Marron TU, Paz-Ares L, Rizvi N, Rudin CM, Shum E, Stahel R, Trunova N, Bunn PA, Hirsch FR. Meyer ML, et al. Among authors: gros l. Ann Oncol. 2024 Dec;35(12):1088-1104. doi: 10.1016/j.annonc.2024.10.006. Epub 2024 Oct 15. Ann Oncol. 2024. PMID: 39413875 Review.
102 results